literature-driven analysis at the intersection of healthcare, economics and policy.
-
Cancer Therapies That Work But NICE Won’t Fund – What They Mean for Patients.
Read more: Cancer Therapies That Work But NICE Won’t Fund – What They Mean for Patients.How do NICE decisions work? The National Institute for Health and Care excellence serves the primary purpose of health technology assessment (HTA). This is achieved in two ways: by providing clinical guidelines on the most appropriate treatments and care regimes and to provide guidance of whether recommended treatments are cost-effective for commission in the NHS. As…
-
GLP-1 Medications: Side effects, Uncertainty and the Socioeconomic Cost of Rapid Adoption
Read more: GLP-1 Medications: Side effects, Uncertainty and the Socioeconomic Cost of Rapid AdoptionGLP-1 receptor agonists have been widely accepted as a phenomena in metabolic health; a “miracle drug”. Originally developed and prescribed for Type 2 Diabetes (T2D), usage has expanded to now cover obesity and weight-related conditions, with the expectation of long-term or lifelong usage. In a relatively short space of time, these medications have entered routine…
-
Prevention: The health inequality contributor that needs more attention
Read more: Prevention: The health inequality contributor that needs more attentionPrevention is the policy we keep ignoring… Modern healthcare systems excel in intervening once people are already unwell – clinicians diagnose, treat, and manage complications whilst we absorb the rise in costs. What these systems are far less structured to do, is prevent the disease from occurring in the first place. An estimated 40% of…
Arussa Beyond the Bench. 